Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders
Autor: | Lloyd Paul Aiello, Robert L. Avery, Paul G. Arrigg, Bruce A. Keyt, Henry D. Jampel, Sabera T. Shah, Louis R. Pasquale, Hagen Thieme, Mami A. Iwamoto, John E. Park, Hung V. Nguyen, Lloyd M. Aiello, Napoleone Ferrara, George L. King |
---|---|
Rok vydání: | 1994 |
Předmět: |
Adult
Male Vascular Endothelial Growth Factor A medicine.medical_specialty Central retinal vein Retinal Disorder Adolescent genetic structures Endothelial Growth Factors Aqueous Humor Neovascularization chemistry.chemical_compound Retinal Diseases Internal medicine Ophthalmology medicine Humans Child Aged Aged 80 and over Lymphokines Diabetic Retinopathy Neovascularization Pathologic Vascular Endothelial Growth Factors business.industry Retinal Vessels Retinal detachment Retinal General Medicine Diabetic retinopathy Middle Aged medicine.disease eye diseases Vitreous Body Vascular endothelial growth factor Endocrinology medicine.anatomical_structure chemistry Vitreous hemorrhage Female sense organs medicine.symptom Extracellular Space business |
Zdroj: | New England Journal of Medicine. 331:1480-1487 |
ISSN: | 1533-4406 0028-4793 |
Popis: | Retinal ischemia induces intraocular neovascularization, which often leads to glaucoma, vitreous hemorrhage, and retinal detachment, presumably by stimulating the release of angiogenic molecules. Vascular endothelial growth factor (VEGF) is an endothelial-cell-specific angiogenic factor whose production is increased by hypoxia.We measured the concentration of VEGF in 210 specimens of ocular fluid obtained from 164 patients undergoing intraocular surgery, using both radioimmuno-assays and radioreceptor assays. Vitreous proliferative potential was measured with in vitro assays of the growth of retinal endothelial cells and with VEGF-neutralizing antibody.VEGF was detected in 69 of 136 ocular-fluid samples from patients with diabetic retinopathy, 29 of 38 samples from patients with neovascularization of the iris, and 3 of 4 samples from patients with ischemic occlusion of the central retinal vein, as compared with 2 of 31 samples from patients with no neovascular disorders (P0.001, P0.001, and P = 0.006, respectively). The mean (+/- SD) VEGF concentration in 70 samples of ocular fluid from patients with active proliferative diabetic retinopathy (3.6 +/- 6.3 ng per milliliter) was higher than that in 25 samples from patients with nonproliferative diabetic retinopathy (0.1 +/- 0.1 ng per milliliter, P = 0.008), 41 samples from patients with quiescent proliferative diabetic retinopathy (0.2 +/- 0.6 ng per milliliter, P0.001), or 31 samples from nondiabetic patients (0.1 +/- 0.2 ng per milliliter, P = 0.003). Concentrations of VEGF in vitreous fluid (8.8 +/- 9.9 ng per milliliter) were higher than those in aqueous fluid (5.6 +/- 8.6 ng per milliliter, P = 0.033) in all 10 pairs of samples obtained simultaneously from the same patient; VEGF concentrations in vitreous fluid declined after successful laser photocoagulation. VEGF stimulated the growth of retinal endothelial cells in vitro, as did vitreous fluid containing measurable VEGF. Stimulation was inhibited by VEGF-neutralizing antibodies.Our data suggest that VEGF plays a major part in mediating active intraocular neovascularization in patients with ischemic retinal diseases, such as diabetic retinopathy and retinal-vein occlusion. |
Databáze: | OpenAIRE |
Externí odkaz: |